Morocco, one of the first African countries to offer shots to children and adolescents, began vaccinating those between ages 12 and 17 in September. The government is aiming to inoculate about six million adolescents in this age group with a single dose of the Pfizer-BioNTech vaccine. South Africa began the immunisation of children aged 12 to 17 in October. Pakistan is currently administering the Pfizer-BioNTech vaccine to children over age 15, and the Chinese Sinovac and Sinopharm vaccines to children over 12. Vaccination for some groups of children could begin in January, news reports say. Bharat Biotech, the makers of the domestically manufactured Covaxin vaccine, sought permission for emergency use in children aged 12 and over, but regulators have yet to announce a decision. It is the world’s first DNA-platform vaccine for COVID-19, but its rollout has not begun. In August, India’s drug regulator approved Zydus Cadila’s needle-free Z圜oV-D vaccine for those aged 12 and above.
Taiwan has temporarily suspended giving second doses of the Pfizer-BioNTech vaccine to children and adolescents between 12 and 17 years over concerns from the risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart), according to media reports.
#Vaccine infographic full#
While some countries are giving children and adolescents the full two-dose course of the Pfizer-BioNTech vaccine, others are giving a single dose.Īccording to the London School of Hygiene & Tropical Medicine, there are 20 vaccine candidates in clinical testing for those under 18.Ĭhina has begun inoculating children aged three and above with its own CoronaVac vaccine, produced by Sinovac Biotech. Three vaccines that have been approved by the World Health Organization (WHO) are being administered to children in various countries: the Pfizer-BioNTech vaccine, the Sinopharm shot and the Sinovac vaccine. While many children who do catch COVID have few to no symptoms, those with underlying health conditions may be at increased risk of severe illness. Mumps and rubella vaccines were authorized in Canada in 1969 and measles live vaccine was authorized in 1963.įor polio, the five years prior to routine vaccine use in Canada were defined as 1950-1954 the vaccine was introduced in 1955.įor diphtheria, the five years prior to routine vaccine use in Canada were defined as 1925-1929 the vaccine was routinely used beginning in 1930.More than 100 countries around the world have extended their COVID-19 vaccination drives to children.Īccording to a report from UNICEF, which analysed 115 million confirmed COVID-19 cases from 105 countries, people under 20 account for 16 percent of reported cases. This is due to the fact that these diseases were temporarily suspended from national surveillance for varying time periods between 19, with declines in physician reporting in the years leading up to 1959. The five years used for the pre-vaccine era were defined as 1950-1954 for measles, mumps and rubella. Some numbers are subject to change as reports are updated.ĭata sources: Measles and rubella data were obtained from the Canadian Measles and Rubella Surveillance System, while data for all other diseases was obtained from the Canadian Notifiable Disease Surveillance System.įor whooping cough (pertussis), the five years prior to vaccine use in Canada were defined as 1938 to 1942 the whole cell pertussis vaccine was authorized in Canada in 1943.
0 kommentar(er)
